Connect Biopharma reports Phase 2 COPD topline: 81% lower treatment failure, plans FDA engagement

Connect Biopharma announced topline Phase 2 results showing rademikibart cut treatment failure by 81% through Week 4 versus placebo.Key Highlights:Original SEC Filing: Connect Biopharma Holdings Ltd [ CNTB ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…